SG11201404014PA - Methods for increasing the infectivity of viruses - Google Patents

Methods for increasing the infectivity of viruses

Info

Publication number
SG11201404014PA
SG11201404014PA SG11201404014PA SG11201404014PA SG11201404014PA SG 11201404014P A SG11201404014P A SG 11201404014PA SG 11201404014P A SG11201404014P A SG 11201404014PA SG 11201404014P A SG11201404014P A SG 11201404014PA SG 11201404014P A SG11201404014P A SG 11201404014PA
Authority
SG
Singapore
Prior art keywords
infectivity
viruses
increasing
methods
Prior art date
Application number
SG11201404014PA
Inventor
Brian Agnew
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Publication of SG11201404014PA publication Critical patent/SG11201404014PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety
SG11201404014PA 2012-01-26 2013-01-25 Methods for increasing the infectivity of viruses SG11201404014PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261591023P 2012-01-26 2012-01-26
PCT/US2013/023045 WO2013112778A1 (en) 2012-01-26 2013-01-25 Methods for increasing the infectivity of viruses

Publications (1)

Publication Number Publication Date
SG11201404014PA true SG11201404014PA (en) 2014-08-28

Family

ID=48873928

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201404014PA SG11201404014PA (en) 2012-01-26 2013-01-25 Methods for increasing the infectivity of viruses

Country Status (7)

Country Link
US (2) US20150017703A1 (en)
EP (1) EP2807251B1 (en)
KR (1) KR20140128966A (en)
CN (1) CN104220588A (en)
AU (1) AU2013212066B2 (en)
SG (1) SG11201404014PA (en)
WO (1) WO2013112778A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DE12722942T1 (en) 2011-03-31 2021-09-30 Modernatx, Inc. RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (en) 2011-10-03 2022-04-07 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
LT2791160T (en) 2011-12-16 2022-06-10 Modernatx, Inc. Modified mrna compositions
EP2807252B1 (en) * 2012-01-26 2017-05-10 Life Technologies Corporation Methods for increasing the infectivity of viruses
CA2868996A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2922554T3 (en) 2012-11-26 2022-06-20 Modernatx, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (en) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Polynucleotide encoding low density lipoprotein receptor
AU2015289583A1 (en) 2014-07-16 2017-02-02 Modernatx, Inc. Chimeric polynucleotides
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
CN111032869B (en) * 2017-07-21 2024-04-16 中国科学院深圳先进技术研究院 Virus transfection synergist and application of virus transfection based on click chemistry
JP7275111B2 (en) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド Method for producing lipid nanoparticles
KR20220094216A (en) 2019-11-08 2022-07-05 코브 테라퓨틱스 Modified adeno-associated viral vectors and their delivery to the central nervous system

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820A (en) * 1846-10-21 Improvement in steam-engines
US7169411B1 (en) * 1997-06-13 2007-01-30 The University of Nebraska Board of Regents Composition for delivery of biological agents and methods for the preparation thereof
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
AU7607900A (en) * 1999-09-22 2001-04-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
US20070020620A1 (en) * 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
DK1987068T3 (en) * 2006-02-10 2018-09-03 Life Technologies Corp OLIGOSACCHARID MODIFICATION AND LABELING OF PROTEINS
EP2362912A1 (en) * 2008-11-14 2011-09-07 Life Technologies Corporation Compositions and methods for engineering cells
US20100203647A1 (en) * 2008-11-21 2010-08-12 The Rockefeller University Chemical Reporters of Protein Acylation

Also Published As

Publication number Publication date
AU2013212066B2 (en) 2018-11-08
AU2013212066A1 (en) 2014-06-26
WO2013112778A1 (en) 2013-08-01
CN104220588A (en) 2014-12-17
KR20140128966A (en) 2014-11-06
EP2807251B1 (en) 2018-01-10
EP2807251A4 (en) 2015-08-12
US20150017703A1 (en) 2015-01-15
US20180201907A1 (en) 2018-07-19
EP2807251A1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
SG11201404014PA (en) Methods for increasing the infectivity of viruses
SG11201404361UA (en) Methods for increasing the infectivity of viruses
IL237275A0 (en) Compounds for the treatment of paramoxyvirus viral infectiones
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
GB201218933D0 (en) An entity
EP2806891A4 (en) Parainfluenza virus 5 based vaccines
GB201321144D0 (en) Improved oncolytic viruses
IL231132A0 (en) Viral clearnce methods
HK1212332A1 (en) Hepatitis c virus inhibitors
IL236450A (en) Process for the preparation of 5-fluoro-1h-pyrazoles
PL399419A1 (en) Process for the preparation of 4-methoxydihydrochalcone
PL399418A1 (en) Process for the preparation of 4-methoxydihydrochalcone
EP2887883A4 (en) Improved scalpel
KR101334557B9 (en) Cookware
ZA201405824B (en) Process for the preparation of substituted phenylpropanones
GB201215184D0 (en) Therapeutic virus
ZA201405954B (en) Method for assessing the viability of viruses with lymphotropism
EP2826486A4 (en) Agent for the treatment of hepatitis c virus
GB201211930D0 (en) Concept for all killer viruses
HU229987B1 (en) Process for the preparation of pyrimidinyl-piperazines
GB201314063D0 (en) Virus
GB201213587D0 (en) Novel endolysin
GB201306812D0 (en) Virus